From Wikipedia, the free encyclopedia
Investigational analgesic drug
DSP-2230
|
|
Routes of administration |
By mouth |
---|
|
(2S)-2-[[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]amino]propanamide
|
CAS Number | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C20H20F3N5O2 |
---|
Molar mass | 419.408 g·mol−1 |
---|
3D model (
JSmol) | |
---|
FC1=CC(OC2=CC=C(N=C3CN([C@@H](C(N([H])[H])=O)C)[H])C(N3C4CCC4)=N2)=CC(F)=C1F
|
InChI=1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m1/s1 Key:HHXCJIMPEJSJTG-SNVBAGLBSA-N
|
DSP-2230 is a
selective
small-molecule
Nav1.7 and
Nav1.8
voltage-gated sodium channel
blocker which is under development by
Dainippon Sumitomo Pharma for the treatment of
neuropathic pain.
[1]
[2] As of June 2014, it is in
phase I/
phase II
clinical trials.
[1]
[2]
See also
References
External links
-
"DSP-2230". AdisInsight. Springer Nature Switzerland AG.
|
---|
Calcium |
VDCCsTooltip Voltage-dependent calcium channels | |
---|
|
---|
Potassium |
VGKCsTooltip Voltage-gated potassium channels | |
---|
IRKsTooltip Inwardly rectifying potassium channel | |
---|
KCaTooltip Calcium-activated potassium channel | |
---|
K2PsTooltip Tandem pore domain potassium channel | |
---|
|
---|
Sodium |
VGSCsTooltip Voltage-gated sodium channels | |
---|
ENaCTooltip Epithelial sodium channel | |
---|
ASICsTooltip Acid-sensing ion channel | |
---|
|
---|
Chloride |
CaCCsTooltip Calcium-activated chloride channel | |
---|
CFTRTooltip Cystic fibrosis transmembrane conductance regulator | |
---|
Unsorted | |
---|
|
---|
Others |
TRPsTooltip Transient receptor potential channels | |
---|
LGICsTooltip Ligand gated ion channels | |
---|
|
---|
|